Well-matched contest in basal insulin market between Sanofi and Novo Nordisk
Competition is getting fiercer in the market of next-generation basal insulin which might replace Lantus. Sanofi and Novo Nordisk are even having a publicity war to show off their companies’ performances.
Novo Nordisk Korea announced its next-generation basal insulin product ‘Tresiba Flextouch I...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
